Clinical Trials
176 trialsKeyPemls-004
Peking Union Medical College Hospital
Biomarker Analysis of Castration-resistant Prostate Cancer Undergoing Treatment With Docetaxel Followed by Enzalutamide
Instituto do Cancer do Estado de São Paulo
NeoPACT
University of Kansas Medical Center
IMAGINE
University Hospital, Essen
Study of Docetaxel and Cisplatin Combined With Nimotuzumab As First-Line Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma
Sun Yat-sen University
SAVE
Hunan Province Tumor Hospital
Adebrelimab Combined With Bevacizumab and Docetaxel for Advanced Non-Squamous Non-small Cell Lung Cancer After Progression on First-line Immunotherapy
The First Affiliated Hospital of Xinxiang Medical College
ALTER-G-001
Ruijin Hospital
CZCNRHNSCC
Sun Yat-sen University
LOTS
National Cheng-Kung University Hospital
B2023-153
Sun Yat-sen University
A Study to Compare the Efficacy and Safety of HB1801 to Taxotere in Advanced Non-Small Cell Lung Cancer (NSCLC)
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Study of KN026 Monotherapy or Combination Therapy in Patients With Metastatic Breast Cancer
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
NCCCNRHNSCC
Sun Yat-sen University
Induction Chemotherapy Combined With Immunotherapy for Locally Advanced Hypopharyngeal Carcinoma
Eye & ENT Hospital of Fudan University
HIST-RIC
Institut Paoli-Calmettes
Induction Chemotherapy Followed by Surgery for Locally Advanced Head and Neck Cancer
George Washington University
Study of Perioperative Chemotherapy Combined With Tislelizumab and Trastuzumab in the Treatment of GC/EGC
The First Affiliated Hospital of Zhengzhou University
A Study of Docetaxel for Injection (Albumin-bound) in Patients With Pancreatic Cancer
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
A Study to Evaluate Serplulimab in Combination With Docetaxel +S-1 VS. Docetaxel +S-1 as Adjuvant Treatment Therapy in Stage IIIc Gastric Cancer
RenJi Hospital
Multidisciplinary Approach for Poor Prognosis Sinonasal Tumors in Operable Patients
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Multidisciplinary Approach for Poor Prognosis Sinonasal Tumors in Inoperable Patients
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Targeted or Chemotherapy Combined With Immunotherapy Versus Chemotherapy for PD-1 Inhibitor Refractory R/M NPC
Sun Yat-sen University
A Study of Docetaxel for Injection (Albumin-bound) in Patients With Gastric Cancer
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Androgen Deprivation Therapy Combined With Docetaxel for High Risk Prostate Cancer
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
CHANCE
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
The Efficacy and Safety of Docetaxel Combined With Platinum for Metastatic Hormone-sensitive Prostate Cancer
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
A Study of Docetaxel for Injection (Albumin-bound) in Combination With Bevacizumab in Patients With Ovarian Cancer
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
A Study of Immunotherapy Combined With Neoadjuvant Therapy Versus Neoadjuvant Therapy for Breast Cancer
Shengjing Hospital
Study of KN026 in Combination With Docetaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Clinical Study of Chidamide Combined With Chemotherapy in Neoadjuvant Treatment of HR+/ HER2-BC
Shengjing Hospital
SABRE
Wuhan University
Pembrolizumab and Bevacizumab With Chemotherapy Followed by Pembrolizumab, Bevacizumab and Olaparib in Recurrent Ovarian Cancer
Saitama Medical University International Medical Center
Phase II Clinical Study of Camrelizumab Combined With Chemotherapy or Anlotinib in Advanced Esophageal Squamous Cell Cancer
Zhejiang Cancer Hospital
An Open Label Phase II Study of Biweekly Docetaxel Plus Androgen-Deprivation Therapy in Patients With Previously-Untreated, Metastatic, Prostatic Adenocarcinoma
Samsung Medical Center
Tislelizumab as Cross-line Treatment for Advanced NSCLC
Fujian Cancer Hospital
HERMET
University of Kansas Medical Center
A Study of Sintilimab Compared With Docetaxel or Pemetrexed as Second-line Treatment for Patients With Stage IV Nonsquamous Non-small Cell Lung Cancer After Failure With Platinum-Containing Chemotherapy
China Three Gorges University, Yichang, China
A Study of Sintilimab or Placebo in Combination With Chemotherapy as Second-line Treatment for Patients With Stage IV Nonsquamous Non-small Cell Lung Cancer With Wild-type EGFR After Failure With Platinum-Containing Chemotherapy.
China Three Gorges University, Yichang, China
A Study of TC(Docetaxel and Carboplatin) Regimen With or Without Nimotuzumab in Recurrent Metastatic Oral Squamous Cell Carcinoma
China Three Gorges University, Yichang, China
Neoadjuvant Camrelizumab Plus Chemotherapy in Triple Negative Breast Cancer
Jilin University
Weekly Docetaxel Plus Cisplatin as First-line Chemotherapy in Metastatic Salivary Gland Cancer Patients : a Multicenter Phase II Study
Samsung Medical Center
Pyrotinib as Neoadjuvant Agent for Non-objective Response HER2-positive Early Breast Cancer
The First Affiliated Hospital with Nanjing Medical University
TKIs vs. Pertuzumab in HER2+ Breast Cancer Patients With Active Brain Metastases (HER2BRAIN)
Second Affiliated Hospital, School of Medicine, Zhejiang University
Apatinib Plus Camrelizumab Combined With Docetaxel and S1 in First-line Treatment for Metastatic Gastric Cancer
Zhongnan Hospital
Efficacy and Safety of Toripalimab Combined With Docetaxel or Nab-paclitaxel in Patients With Advanced Gastric Cancer
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
A Study of SHR3680 in Combination With Docetaxel in the Treatment of mCRPC
Jiangsu HengRui Medicine Co., Ltd.
Toripalimab Combined With FLOT Neoadjuvant Chemotherapy in Patients With Resectable Gastric Cancer
Tianjin Medical University Cancer Institute and Hospital
A Single-arm, Phase â…¡ Clinical Trial of Anlotinib Hydrochloride Combined With Irinotecan or Docetaxel for Second Line Treatment of Nonsensitive Relapsed Small-cell Lung Cancer
First People's Hospital of Hangzhou
B-DOCT
The Netherlands Cancer Institute